CLOSINGS: View Closings

Gene therapy for rare retinal disorder to cost $425,000 per eye

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited ...

Posted: Jan 4, 2018 8:16 AM
Updated: Jan 4, 2018 8:16 AM

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited disorder, will cost $425,000 per eye.

Spark Therapeutics Inc., the Philadelphia-based maker of voretigene neparvovec, announced Wednesday in a statement that it reached an agreement in principle with Harvard Pilgrim and affiliates of-Express Scripts to make the one-time treatment available to patients with a rare genetic defect that often leads to blindness.

Luxturna, a one-time treatment, corrects a genetic mutation that can lead to blindness

Spark Therapeutics set the price for the gene therapy at $425,000 per eye

The mutation affects both eyes, usually at the same pace, so most patients would need treatment for both eyes, a Spark Therapeutics spokeswoman said.

In some cases, the gene therapy will be available under an "outcomes-based rebate arrangement." The company also stated that its proposal to the Centers for Medicare and Medicaid Services, the government program that covers about 100 million Americans, would allow installment payments for the drug.

"For a one-time therapy, like Luxturna, a non-traditional payment and distribution model is necessary to ensure needs of all parties -- patients, payers and providers -- are addressed," said Jennifer Luddy, a spokeswoman for Express Scripts.

At least one patient advocate disagrees.

"The new payment models announced today are merely a way to disguise a price that is simply too high," David Mitchell, president and founder of Patients For Affordable Drugs, said in a statement. "Spark Therapeutics is charging as much for Luxturna as they think they can get away with."

Spark Therapeutics CEO Jeff Marrazzo co-authored a recent blog post in the journal Health Affairs that said "the current payment system -- accustomed to ongoing treatment of chronic diseases -- creates significant challenges" for gene therapies and other treatments.

One-time-only treatments for rare genetic disorders are still unique, he noted.

The drug is intended for patients with retinal dystrophy due to a mutation of the RPE65 gene. This rare genetic defect causes severe visual impairment beginning in infancy and can eventually lead to blindness. The company believes the total "population in the US, Europe and select additional markets in the Americas and Asia/Pacific is up to approximately 6,000 individuals" who have the mutation targeted by Luxturna, explained Monique da Silva, a spokeswoman for Spark Therapeutics.

The drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.

Luxturna is only the third gene therapy approved for use in the United States; two others were also approved in 2017. This is the first to correct an inherited genetic mutation.

Luxturna-is a liquid that is injected directly into the eye with a microscopic needle during a surgical procedure. The drug supplies a third gene -- a normal RPE65 gene -- to cells in the retina, a layer of tissue lining the back of the eye.-This third version of the gene does not remove or replace the two mutated genes causing the disease, which remain inside the cells. However, the normal gene delivered by the treatment is able to function within the retinal cells and correct vision problems.

In the phase 3 clinical trial, 27 out of 29 participants -- 93% -- who received the gene therapy demonstrated a gain in functional vision as assessed by a mobility test performed in a maze, according to the company. Risks of the treatment include cataracts, elevated eye pressure, retinal tears and holes and inflammation.

The company's offer of unusual payer models, including rebates and installment payments, will "help ensure patients' individual financial situation does not hinder access to treatment," da Silva said.

"New technologies such as gene and cell therapies hold out the potential to transform medicine," FDA Commissioner Dr. Scott Gottlieb-said in a statement announcing the August approval of Kymriah, considered to be the first gene therapy to be approved for the US market.

Kymriah is a leukemia treatment made by pharmaceutical giant Novartis. Similar to Luxturna, Kymriah is a one-time treatment, and its price tag is $475,000. However, Novartis said this price will not be charged to patients who do not respond within a month of treatment.

Minnesota Coronavirus Cases

Data is updated nightly.

Cases: 312969

Reported Deaths: 3637
CountyCasesDeaths
Hennepin661641115
Ramsey27766505
Anoka22149228
Dakota22015190
Washington13999115
Stearns13733116
St. Louis8747112
Scott846255
Wright775843
Olmsted665634
Sherburne587641
Clay498457
Carver474213
Blue Earth414116
Rice412836
Kandiyohi408122
Crow Wing359634
Otter Tail314322
Chisago311611
Nobles308730
Benton299451
Winona276930
Mower261623
Douglas260337
Polk256324
Morrison231629
Lyon218711
Beltrami217117
McLeod212812
Becker205415
Goodhue203228
Steele19497
Isanti190617
Itasca190423
Carlton185816
Todd181214
Nicollet162525
Mille Lacs153631
Freeborn15336
Le Sueur147011
Cass143710
Brown141315
Waseca139211
Pine13658
Meeker12879
Roseau11964
Hubbard114925
Martin113320
Wabasha10561
Redwood94619
Chippewa8877
Cottonwood8664
Renville86527
Dodge8600
Watonwan8544
Wadena8016
Sibley7934
Rock7779
Aitkin76730
Pipestone72518
Fillmore6990
Houston6984
Yellow Medicine64812
Pennington6478
Kanabec61913
Murray5873
Swift5838
Faribault5612
Pope5391
Clearwater5248
Stevens5103
Marshall4979
Unassigned49359
Jackson4881
Lake4226
Koochiching3926
Wilkin3895
Lac qui Parle3773
Lincoln3591
Norman3497
Big Stone3182
Mahnomen2964
Grant2796
Kittson2248
Red Lake2133
Traverse1481
Lake of the Woods1001
Cook720

Iowa Coronavirus Cases

Data is updated nightly.

Cases: 227398

Reported Deaths: 2368
CountyCasesDeaths
Polk33642336
Linn14352165
Scott1124986
Black Hawk10893135
Woodbury10372126
Johnson955336
Dubuque923291
Story678822
Dallas637257
Pottawattamie631970
Sioux370325
Webster358535
Cerro Gordo357144
Marshall348546
Clinton331344
Buena Vista305414
Des Moines291520
Muscatine289268
Warren281914
Plymouth276042
Wapello255772
Jones232313
Jasper217944
Marion205320
Lee203917
Carroll198422
Bremer195212
Henry18307
Crawford174616
Benton170619
Tama154340
Jackson144613
Delaware144221
Washington141314
Dickinson139210
Boone137011
Mahaska126827
Wright12456
Clay11784
Buchanan117010
Hardin115810
Page11374
Hamilton11199
Clayton11175
Cedar108413
Harrison107729
Kossuth10667
Calhoun10617
Floyd105016
Mills10487
Fayette103910
Lyon10338
Butler10216
Poweshiek99313
Winneshiek97613
Iowa95812
Winnebago93023
Hancock8677
Grundy86311
Louisa86216
Sac8608
Chickasaw8574
Cherokee8484
Allamakee81811
Cass81623
Mitchell7984
Appanoose79312
Humboldt7715
Union7706
Shelby76511
Emmet76424
Guthrie75415
Franklin73921
Jefferson7142
Madison6864
Unassigned6690
Palo Alto6554
Keokuk5997
Howard5599
Pocahontas5584
Greene5250
Osceola5241
Ida48913
Clarke4874
Davis4709
Taylor4653
Montgomery46311
Monroe44412
Adair4418
Monona4352
Worth3630
Fremont3583
Van Buren3585
Lucas3256
Decatur3170
Wayne3007
Audubon2962
Ringgold2112
Adams1702
Rochester
Clear
28° wxIcon
Hi: 28° Lo: 14°
Feels Like: 19°
Mason City
Clear
30° wxIcon
Hi: 30° Lo: 14°
Feels Like: 23°
Albert Lea
Clear
28° wxIcon
Hi: 30° Lo: 15°
Feels Like: 22°
Austin
Clear
28° wxIcon
Hi: 30° Lo: 14°
Feels Like: 21°
Charles City
Clear
28° wxIcon
Hi: 29° Lo: 14°
Feels Like: 19°
Colder Conditions To Start The Workweek
KIMT Radar
KIMT Eye in the sky

Latest Video

Image

Kindness tree on display in Rochester

Image

Advice for safe holiday decorating

Image

Aaron's Sunday Night Forecast

Image

Active shooter police standoff resolved after 9 hours

Image

Standoff in Albert Lea after 3 people shot

Image

Christmas tree shopping

Image

MC 'grateful' to play, adjusting with schedule changes

Image

Small business Saturday

Image

Sean's Weather 11/28

Image

Sidelined in quarantine: Coach Fennelly talks about his experience away from the game

Community Events